SCHEMBL16396880

SCHEMBL16396880

CC(C)(C)OC(=O)NCc1cccc(-c2cc(COc3ccccc3CC(=O)O)cc(NCC3CCCO3)c2F)c1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 1/20 0.41
▸ PTGER1 P34995 1/20 0.40
▸ PTGER4 P35408 1/20 0.40
▸ PTGER3 P43115 1/20 0.40
▸ PTGER2 P43116 1/20 0.40
▸ CFD P00746 9/20 0.39
▸ F11 P03951 6/20 0.39
▸ TPSB2 P20231 5/20 0.39
▸ KLKB1 P03952 2/20 0.39
▸ PLG P00747 1/20 0.39
▸ PLAU P00749 1/20 0.39
▸ F7 P08709 1/20 0.39
▸ CCR5 P51681 1/20 0.39
▸ LMNA P02545 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ BRD4 O60885 1/20 0.37
▸ CREBBP Q92793 1/20 0.37
▸ CYP1A2 P05177 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16396630 0.95 HPGD (0.41) HPGDCCR5LMNAL3MBTL1BRD4
SCHEMBL16397048 0.88 CFD (0.54) PTGER1PTGER4PTGER3PTGER2CFD
SCHEMBL16397586 0.83 CFD (0.55) HPGDPTGER1PTGER4PTGER3PTGER2
SCHEMBL16410444 0.79 CFD (0.44) HPGDCFDF11TPSB2KLKB1
SCHEMBL16396177 0.79 HPGD (0.49) HPGDCCR5LMNAL3MBTL1
SCHEMBL17764513 0.78 CFD (0.41) HPGDPTGER1PTGER4PTGER3PTGER2
SCHEMBL17764515 0.78 CFD (0.41) HPGDPTGER1PTGER4PTGER3PTGER2
SCHEMBL17764529 0.78 CFD (0.41) HPGDPTGER1PTGER4PTGER3PTGER2
SCHEMBL16396514 0.78 HPGD (0.46) HPGDCCR5LMNAL3MBTL1
SCHEMBL16402498 0.77 CFD (0.54) HPGDCFDF11TPSB2KLKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160145247-A1 Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof NOVARTIS AG (CH) 2016-05-26 — — US disclosed
EP-3022182-A1 AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF Novartis AG (CH) 2016-05-25 — — EP disclosed
WO-2015009977-A1 AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF NOVARTIS AG (CH) 2015-01-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160145247-A1 Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof CFD, CFH, CFB HPGD 1155/4885PTGER1 1777/4885PTGER4 1998/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback